Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Herrmann

Showing results (411-420 of 498) with videos related to

Pageof 50
Sort By:
Radiology|June 1, 1997
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal stagingF Moog, M Bangerter, C G Diederichs, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistanceT Licht, K J Bross, H H Fiebig, et al.
The Journal of Pathology|August 9, 2005
Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel diseaseI Szanto, L Rubbia-Brandt, P Kiss, et al.
American Journal of Clinical Oncology|January 1, 1991
Clinical effects of recombinant human interleukin-3A Ganser, A Lindemann, G Seipelt, et al.
European Journal of Biochemistry|December 15, 1993
Equine infectious anemia virus Tat is a predominantly helical proteinH Sticht, D Willbold, P Bayer, et al.
Molecular and Cellular Biology|July 1, 1996
The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteinsR R Schumann, C J Kirschning, A Unbehaun, et al.
Endoscopy International Open|April 21, 2021
Functional endoscopy in neurogenic dysphagia: a feasibility study focusing on the esophageal phase of swallowingJan Rückert, Philipp Lenz, Hauke Heinzow, et al.
Blood|May 15, 1992
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I studyA Ganser, A Lindemann, O G Ottmann, et al.
Biotechnology Therapeutics|January 1, 1991
Results of phase I/II trials with recombinant human interleukin-3A Ganser, O G Ottmann, G Seipelt, et al.
British Journal of Cancer|June 1, 1995
Is neuroblastoma screening evaluation needed and feasible?J Estève, L Parker, P Roy, et al.
Pageof 50

Showing results (411-420 of 498) with videos related to

Sort By:
Pageof 50
Radiology|June 1, 1997
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal stagingF Moog, M Bangerter, C G Diederichs, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistanceT Licht, K J Bross, H H Fiebig, et al.
The Journal of Pathology|August 9, 2005
Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel diseaseI Szanto, L Rubbia-Brandt, P Kiss, et al.
American Journal of Clinical Oncology|January 1, 1991
Clinical effects of recombinant human interleukin-3A Ganser, A Lindemann, G Seipelt, et al.
European Journal of Biochemistry|December 15, 1993
Equine infectious anemia virus Tat is a predominantly helical proteinH Sticht, D Willbold, P Bayer, et al.
Molecular and Cellular Biology|July 1, 1996
The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteinsR R Schumann, C J Kirschning, A Unbehaun, et al.
Endoscopy International Open|April 21, 2021
Functional endoscopy in neurogenic dysphagia: a feasibility study focusing on the esophageal phase of swallowingJan Rückert, Philipp Lenz, Hauke Heinzow, et al.
Blood|May 15, 1992
Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I studyA Ganser, A Lindemann, O G Ottmann, et al.
Biotechnology Therapeutics|January 1, 1991
Results of phase I/II trials with recombinant human interleukin-3A Ganser, O G Ottmann, G Seipelt, et al.
British Journal of Cancer|June 1, 1995
Is neuroblastoma screening evaluation needed and feasible?J Estève, L Parker, P Roy, et al.
Pageof 50